Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Multiple risk factors were associated with denials and longer wait times for biologic treatment in moderate to severe asthma, ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns. Click to read why VRNA is a Hold.

Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant reductions were also seen in disease severity and itch Dupixent also ...

After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...

Kwiatek and colleagues evaluated 10,088 adults diagnosed with asthma who received an approved biologic therapy — omalizumab (Xolair; Genentech, Novartis), dupilumab (Dupixent; Sanofi ...

Dupixent Market Report 2025 The Business Research Company's Global Dupixent Market Outlook 2025-2034: Growth Drivers, Share, And Trends ...

Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal ...

AEs more commonly observed with Dupixent compared to placebo in at least 3 patients included peripheral edema (n=8 vs. n=5), arthralgia (n=5 vs. n=3), back pain (n=4 vs. n=2), blurred vision (n=4 vs.